Enterprise Value

864.9B

Cash

2.652B

Avg Qtr Burn

N/A

Short % of Float

0.72%

Insider Ownership

0.16%

Institutional Own.

83.69%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Kisunla (Donanemab) Details
Alzheimer's disease

Approved

Quarterly sales

Jaypirca® Pirtobrutinib Details
Cancer, Chronic lymphocytic leukemia, Lymphoma, Blood cancer, Small lymphocytic lymphoma

Approved

Quarterly sales

Jaypirca (pirtobrutinib) Details
Blood cancer, Cancer, Lymphoma, Mantle cell lymphoma

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Jardiance® (empagliflozin) (anti-SGLT2) Details
Diabetes, Type 2 diabetes, Chronic kidney disease

Approved

Quarterly sales

Lebrikizumab Details
Skin disease/disorder, Atopic dermatitis

BLA

FDA meeting

Retevmo +/- pembrolizumab Details
Non-small cell lung carcinoma

Phase 3

Data readout

Abemaciclib Details
Castration-resistant prostate cancer

Phase 3

Data readout

Phase 3

Data readout

Remternetug Details
Alzheimer's disease

Phase 3

Data readout

Mirikizumab Details
Crohns disease

Phase 3

Update

Pirtobrutinib Details
Cancer, Blood cancer, Lymphoma, Chronic lymphocytic leukemia

Phase 3

Update

Phase 3

Update

Tirzepatide Details
Obstructive sleep apnea , Sleeping disorder

Phase 3

Update

Retevmo Details
Medullary Thyroid Cancer

Phase 3

Update

Orforglipron Details
Type 1 diabetes

Phase 3

Update

Phase 3

Update

Phase 3

Initiation

Phase 2b

Update

Tirzepatide Details
metabolic dysfunction-associated steatohepatitis , Liver fibrosis

Phase 2

Update

Peresolimab /LY3462817 Details
Autoimmune disease, Rheumatoid arthritis

Phase 2

Update

Phase 2

Update

Phase 1/2

Update

DC-853 Details
Inflammatory disease, Autoimmune disease

Phase 1

Update

AK-OTOF Details
OTOF-mediated hearing loss

Phase 1

Update